Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease

Jing Zhang, Dave R. Goodlett, Joseph Quinn, Elaine Peskind, Jeffrey Kaye, Yong Zhou, Catherine Pan, Eugene Yi, Jimmy Eng, Qin Wang, Ruedi H. Aebersold, Thomas J. Montine

Research output: Contribution to journalArticle

147 Citations (Scopus)

Abstract

Biomarkers to assist in the diagnosis and medical management of Alzheimer disease (AD) are a pressing need. We have employed a proteomic approach, microcapillary liquid chromatography mass spectrometry of proteins labeled with isotope-coded affinity tags (ICAT), to quantify relative changes in the proteome of human cerebrospinal fluid (CSF) obtained from the lumbar cistern. Using CSF from well-characterized AD patients and age-matched controls at 2 different institutions, we quantified protein concentration ratios of 42% of the 390 CSF proteins that we have identified and found differences ≥ 20% in over half of them. We confirmed our findings by western blot and validated this approach by quantifying relative levels of amyloid precursor protein and cathepsin B in 17 AD patients and 16 control individuals. Quantitative proteomics of CSF from AD patients compared to age-matched controls, as well as from other neurodegenerative diseases, will allow us to generate a roster of proteins that may serve as specific biomarker panels for AD and other geriatric dementias.

Original languageEnglish (US)
Pages (from-to)125-133
Number of pages9
JournalJournal of Alzheimer's Disease
Volume7
Issue number2
StatePublished - 2005

Fingerprint

Proteomics
Cerebrospinal Fluid
Alzheimer Disease
Biomarkers
Cerebrospinal Fluid Proteins
Cathepsin B
Proteins
Proteome
Amyloid
Liquid Chromatography
Isotopes
Geriatrics
Neurodegenerative Diseases
Dementia
Mass Spectrometry
Western Blotting

Keywords

  • Alzheimer disease
  • Biomarkers
  • Cerebrospinal fluid
  • Proteomics

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology

Cite this

Zhang, J., Goodlett, D. R., Quinn, J., Peskind, E., Kaye, J., Zhou, Y., ... Montine, T. J. (2005). Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. Journal of Alzheimer's Disease, 7(2), 125-133.

Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. / Zhang, Jing; Goodlett, Dave R.; Quinn, Joseph; Peskind, Elaine; Kaye, Jeffrey; Zhou, Yong; Pan, Catherine; Yi, Eugene; Eng, Jimmy; Wang, Qin; Aebersold, Ruedi H.; Montine, Thomas J.

In: Journal of Alzheimer's Disease, Vol. 7, No. 2, 2005, p. 125-133.

Research output: Contribution to journalArticle

Zhang, J, Goodlett, DR, Quinn, J, Peskind, E, Kaye, J, Zhou, Y, Pan, C, Yi, E, Eng, J, Wang, Q, Aebersold, RH & Montine, TJ 2005, 'Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease', Journal of Alzheimer's Disease, vol. 7, no. 2, pp. 125-133.
Zhang, Jing ; Goodlett, Dave R. ; Quinn, Joseph ; Peskind, Elaine ; Kaye, Jeffrey ; Zhou, Yong ; Pan, Catherine ; Yi, Eugene ; Eng, Jimmy ; Wang, Qin ; Aebersold, Ruedi H. ; Montine, Thomas J. / Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. In: Journal of Alzheimer's Disease. 2005 ; Vol. 7, No. 2. pp. 125-133.
@article{6d755d0302714111a6aaa5c9f5edac43,
title = "Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease",
abstract = "Biomarkers to assist in the diagnosis and medical management of Alzheimer disease (AD) are a pressing need. We have employed a proteomic approach, microcapillary liquid chromatography mass spectrometry of proteins labeled with isotope-coded affinity tags (ICAT), to quantify relative changes in the proteome of human cerebrospinal fluid (CSF) obtained from the lumbar cistern. Using CSF from well-characterized AD patients and age-matched controls at 2 different institutions, we quantified protein concentration ratios of 42{\%} of the 390 CSF proteins that we have identified and found differences ≥ 20{\%} in over half of them. We confirmed our findings by western blot and validated this approach by quantifying relative levels of amyloid precursor protein and cathepsin B in 17 AD patients and 16 control individuals. Quantitative proteomics of CSF from AD patients compared to age-matched controls, as well as from other neurodegenerative diseases, will allow us to generate a roster of proteins that may serve as specific biomarker panels for AD and other geriatric dementias.",
keywords = "Alzheimer disease, Biomarkers, Cerebrospinal fluid, Proteomics",
author = "Jing Zhang and Goodlett, {Dave R.} and Joseph Quinn and Elaine Peskind and Jeffrey Kaye and Yong Zhou and Catherine Pan and Eugene Yi and Jimmy Eng and Qin Wang and Aebersold, {Ruedi H.} and Montine, {Thomas J.}",
year = "2005",
language = "English (US)",
volume = "7",
pages = "125--133",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "2",

}

TY - JOUR

T1 - Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease

AU - Zhang, Jing

AU - Goodlett, Dave R.

AU - Quinn, Joseph

AU - Peskind, Elaine

AU - Kaye, Jeffrey

AU - Zhou, Yong

AU - Pan, Catherine

AU - Yi, Eugene

AU - Eng, Jimmy

AU - Wang, Qin

AU - Aebersold, Ruedi H.

AU - Montine, Thomas J.

PY - 2005

Y1 - 2005

N2 - Biomarkers to assist in the diagnosis and medical management of Alzheimer disease (AD) are a pressing need. We have employed a proteomic approach, microcapillary liquid chromatography mass spectrometry of proteins labeled with isotope-coded affinity tags (ICAT), to quantify relative changes in the proteome of human cerebrospinal fluid (CSF) obtained from the lumbar cistern. Using CSF from well-characterized AD patients and age-matched controls at 2 different institutions, we quantified protein concentration ratios of 42% of the 390 CSF proteins that we have identified and found differences ≥ 20% in over half of them. We confirmed our findings by western blot and validated this approach by quantifying relative levels of amyloid precursor protein and cathepsin B in 17 AD patients and 16 control individuals. Quantitative proteomics of CSF from AD patients compared to age-matched controls, as well as from other neurodegenerative diseases, will allow us to generate a roster of proteins that may serve as specific biomarker panels for AD and other geriatric dementias.

AB - Biomarkers to assist in the diagnosis and medical management of Alzheimer disease (AD) are a pressing need. We have employed a proteomic approach, microcapillary liquid chromatography mass spectrometry of proteins labeled with isotope-coded affinity tags (ICAT), to quantify relative changes in the proteome of human cerebrospinal fluid (CSF) obtained from the lumbar cistern. Using CSF from well-characterized AD patients and age-matched controls at 2 different institutions, we quantified protein concentration ratios of 42% of the 390 CSF proteins that we have identified and found differences ≥ 20% in over half of them. We confirmed our findings by western blot and validated this approach by quantifying relative levels of amyloid precursor protein and cathepsin B in 17 AD patients and 16 control individuals. Quantitative proteomics of CSF from AD patients compared to age-matched controls, as well as from other neurodegenerative diseases, will allow us to generate a roster of proteins that may serve as specific biomarker panels for AD and other geriatric dementias.

KW - Alzheimer disease

KW - Biomarkers

KW - Cerebrospinal fluid

KW - Proteomics

UR - http://www.scopus.com/inward/record.url?scp=20944443414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20944443414&partnerID=8YFLogxK

M3 - Article

C2 - 15851850

AN - SCOPUS:20944443414

VL - 7

SP - 125

EP - 133

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 2

ER -